Back to press releases
LONDON, UK, 14 December 2009 – Optos plc (LSE:OPTS), a leading medical retinal imaging company, today announced that Dr. John Padfield will retire from his position as Chairman of the Board on 31 December 2009 and will cease to be a Director at that time. Dr. Padfield will be succeeded as Chairman by Dr. Peter Fellner who will join the Board on 1 January 2010.
Dr. Padfield was appointed to the Board in November 2005 and became Chairman in January 2006 prior to the flotation of the Company on the London Stock Exchange in February 2006. Since then Optos has established itself as the leader in ultra-wide field imaging of the retina and has continued to develop its business in the US and Europe with revenues of $97.2m for the year ending 30 September 2009.
Dr. Padfield will be succeeded as Chairman by Dr. Peter Fellner who will join the Board on 1 January 2010. Dr. Fellner is currently Chairman of the medical devices company Consort Medical plc, and of the biotechnology companies Vernalis plc and Astex Therapeutics Ltd. He is also a non-executive director of the global biopharmaceutical company UCB SA and the European bioscience companies Evotec AG and Biotie Therapies Corp. Previously Dr. Fellner was CEO and then Chairman of Celltech Group plc, and oversaw its growth and development into the largest UK biotechnology company, and a FTSE 100 constituent, before its sale for £1.53 billion in 2004. More recently he also
served as Chairman of Acambis plc and Premier Research Group plc, until they were each acquired during 2008.
Commenting Dr. Padfield said: “During the past couple of years the Board has been highly active in assembling a strong management team to fulfil the potential of the Company’s world-leading technology and optomap® imaging.
The appointment of Roy Davis as CEO in 2008 has successfully provided a new focus for Optos. Roy has created a new strategy for the Company that requires execution and expansion over the coming years. Now is the time for a new Chairman to provide the leadership to the Board during this next phase and I am delighted that Peter Fellner will be taking on this role. Optos will benefit from Peter’s extensive experience of public companies in the healthcare field. I wish him, Roy and all the Optos team continued success.”
Dr. Fellner added: “I am very pleased to be joining Optos, which I believe possesses outstanding technology and exceptional potential for further value creation. John Padfield and his Board colleagues have created a robust platform for future growth, and engaged an excellent management team. I very much look forward to joining them in the New Year.”
There are no further details to be disclosed in relation to the Financial Services Authority UK Listing Rules and Forms TM01 and AP01 respectively confirming the resignation of Dr Padfield and appointment of Dr Fellner have been submitted to the Registrar of Companies.
Enquiries
FD
Ben Atwell / Mo Noonan |
Tel: 020 7831 3113 |
About Optos Plc
Optos plc is a leading retinal imaging company. Our vision is to be recognised as the leading provider of retinal diagnostics through leveraging our unique wide-field imaging technology. Both eye and noneye diseases often first exhibit in the periphery of the retina. These are very difficult to detect clinically with conventional examination equipment and techniques. Optos' devices produce ultra wide-field, highresolution images of approximately 82% of the retina, something no other device is capable of doing in any one image. The images provide optometrists and ophthalmologists with enhanced clinical information which facilitates the early detection, management and treatment of disorders and diseases evidenced in the retina such as retinal detachments and tears, glaucoma, diabetic retinopathy and agerelated macular degeneration. Retinal imaging can also indicate evidence of non-eye or systemic diseases such as hypertension and certain cancers. Optos has a range of medical devices that support different customer segments and patient levels: the P200 device is concentrated on wellness screening carried out by optometrists and ophthalmologists in primary care; the P200C device is designed to meet the need for more exacting clinical imaging capabilities and standards in secondary care within the ophthalmology market and at optometric practices that are clinically managing a patient base with advanced ocular disease; and the P200MA device supports retinal specialists, working primarily with a diabetic patient base, in the medical care market through an advanced medical angiography procedure. Optos' technology provides an unequalled combination of wide-field retinal imaging, speed and convenience for the practitioner and patient resulting in more targeted treatment regimes and improved patient outcomes. 75% of all blindness can be treated or prevented if diagnosed early enough and our Optos technology supports this objective.
For more information please visit our website www.optos.com
Forward-Looking Statements
Certain statements made in this announcement are forward-looking statements. These forward-looking statements are not historical facts but rather are based on the Company's current expectations, estimates and projections about its industry, its beliefs and assumptions. Words such as 'anticipates,' 'expects,' 'intends,' 'plans,' 'believes,' 'seeks,' 'estimates,' and similar expressions are intended to identify forward-looking statements. These statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and other factors, some of which are beyond the Company's control, are difficult to predict and could cause actual results to differ materially from those expressed or forecasted in the forward-looking statements. The Company cautions shareholders and prospective shareholders not to place undue reliance on these forward-looking statements, which reflect the view of the Company only as of the date of this announcement. The forward-looking statements made in this announcement relate only to events as of the date on which the statements are made. The Company will not undertake any obligation to release publicly any revisions or updates to these forward-looking statements to reflect events, circumstances or unanticipated events occurring after the date of this announcement except as required by law or by any appropriate regulatory authority.